The Business Intelligence firm La Merie S.L. conducted an analysis of the R&D pipeline of human growth hormone (hGH, somatropin). The study revealed that Sandoz (the generic division of Novartis) sells the biogeneric somatropin as Omnitrope at a 25 % discount but only achieved 2007 sales of about US$ 8 mln representing a 0.3 % share of the worldwide hGH market in 2007 of US$ 2.7 bln (published data only).
FULL STORY

Source: Pharma Industry / Biotech Industry News From Medical News Today